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a b s t r a c t 
The Epstein–Barr virus induced gene 2 (EBI2) was recently identiﬁed as the ﬁrst oxysterol-activated 7TM 
receptor. EBI2 is essential for B cell trafﬁcking within lymphoid tissues and thus the humoral immune 
response in general. Here we characterize the antagonism of the non-peptide molecule GSK682753A, 
which blocks oxysterol-induced G-protein activation, β-arrestin recruitment and B-cell chemotaxis. We 
furthermore demonstrate that activation triggers pertussis toxin-sensitive MAP kinase phosphoryla- 
tion, which is also inhibited by GSK682753A. Thus, EBI2 signalling in B cells mediates key phenotypic 
functions via signalling pathways amenable to manipulation providing additional therapeutic options 
for inhibiting EBI2 activity. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY-NC-ND license. . Introduction 
The Epstein–Barr virus induced gene 2 (EBI2 also known as 
PR183) is a G protein-coupled seven-transmembrane (7TM) recep- 
or that is predominantly expressed in B and T cells [ 1 , 2 ]. It regulates 
he trafﬁcking of B cells within lymphoid tissues and is highly impor- 
ant for the generation of humoral immune responses [ 3 , 4 ]. EBI2 re- 
ained orphan for years; however, two independent studies recently 
howed that this receptor is activated by oxysterols, most potently by 
 α,25-dihydroxycholesterol (7 α,25-OHC) [ 5 , 6 ]. Binding of oxysterols 
o EBI2 induce G αi activation, β-arrestin recruitment and ultimately 
igration of EBI2-expressing B and T cells. Thus, EBI2 functions as a 
hemo-attractant receptor. Interestingly, the main oxysterol gener- 
ting cells within the lymphoid tissue were recently shown to be of 
tromal origin and these are required for efﬁcient T cell-dependent 
lasma cell responses [ 7 ]. Moreover, we [ 8 , 9 ] and others [ 10 ] iden-
iﬁed residues critical for oxysterol binding to EBI2 showing that the 
ain anchor points are found in TM-II, -III, -VI and ECL2 of which Abbreviations: 7 α,25-OHC, 7 α,25-dihydroxycholesterol; 7TM, seven- 
ransmembrane; EBI2, Epstein–Barr virus induced gene 2; PTLD, post transplantation 
ymphoproliferative disorder; OE, over-expression; ptx, pertussis toxin.. 
* Corresponding author. Tel.: + 45 30604608; fax: + 45 35327610. 
E-mail address: rosenkilde@sund.ku.dk (M.M. Rosenkilde). 
211-5463  c © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europe
ttp://dx.doi.org/10.1016/j.fob.2013.02.003 several are located in the minor binding pocket [ 11 ]. 
The expression of EBI2 has been found to be dysregulated in 
several types of B cell malignancies and is thus reduced in e.g. dif- 
fuse large B-cell lymphomas [ 12 ] and chronic lymphocytic leukemia 
[ 13 ] and increased in post-transplantation lymphoproliferative dis- 
orders (PTLDs) [ 14 ]. EBI2 is also highly expressed in EBV-transformed 
lymphoblastoid B cells which phenotypically resemble PTLDs [ 15 ]. 
We recently showed that increased expression of EBI2 potentiates 
antibody-induced proliferation in B cells [ 16 ]. Thus, in malignan- 
cies where EBI2 expression is increased, this receptor may con- 
tribute to pathogenesis possibly by potentiating B cell proliferation. 
In such cases, blocking EBI2 activity could serve as a target for phar- 
macotherapy. Furthermore, this could also be envisioned to apply 
in autoantibody-mediated diseases such as lupus and rheumatoid 
arthritis. Finally, the up-regulation of EBI2 upon EBV infection may 
function to position B cells in speciﬁc lymphoid zones in order to 
increase overall viral survival. Blocking EBI2 activity may therefore 
serve as a novel route to treat EBV infection as no EBV-speciﬁc drugs 
are currently available. Of note, EBI2 is expressed both in the latent 
and lytic infection stages as opposed to e.g. the EBV-encoded 7TM 
receptor BILF1 or other EBV genes [ 1 , 17 ]. The desire to develop tool 
compounds for modulating EBI2 activity is exempliﬁed well by an 
ongoing uHTS screen at the Sanford-Burnham Center for Chemical 
Genomics where a range of compounds able to antagonize 7 α,25- 
OHC-mediated β-arrestin recruitment has been identiﬁed in a pri- 
mary screen (PubChem BioAssay ID: 651636). an Biochemical Societies. Open access under CC BY-NC-ND license.
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 Simultaneous to the deorphanization of EBI2, we provided a char-
acterization of a non-peptide inverse agonist (coined GSK682753A)
that suppressed the apparent constitutive activity of the receptor [ 16 ].
Here we investigate the antagonistic properties of this compound and
ﬁnd that it potently suppresses 7 α,25-OHC-mediated G αi activation,
β-arrestin recruitment and chemotaxis of primary B cells ex vivo . Fur-
thermore, for the ﬁrst time we demonstrate that 7 α,25-OHC-induced
activation of EBI2 triggers pertussis toxin (ptx)-sensitive MAP kinase
phosphorylation which also is suppressed by GSK682753A. 
2. Materials and methods 
2.1. Ligands 
7 α,25-OHC was purchased from Avanti Polar Lipids and
GSK682753A was synthesized in-house at GlaxoSmithKline. Both
were dissolved in DMSO; ﬁnal DMSO concentration was 0.1%. 
2.2. Transfection and cell culture 
CHO cells were grown in RPMI1640 containing 10% FBS, 2 mM glu-
tamine, 180 u / mL penicillin and 45 μg / mL streptomycin (PenStrep) at
5% CO 2 and 37 
◦C. Stably transfected CHO FLP-In cells were grown in
the same medium also containing 600 μg / mL Hygromycin. The CHO-
K1 EA-arrestin cell line was grown in F-12 HAM medium containing
10% FBS, PenStrep and 250 μg / mL Hygromycin. 
2.3. Receptor constructs 
All constructs contained an N-terminal M1-FLAG tag to facilitate
immunostaining. This does not affect the ligand-induced activity of
EBI2. Mutations were generated using the Quick Change protocol. 
2.4. Membrane preparation 
Membrane preparations of CHO Flp-In cells stably expressing M1-
EBI2 wt or pcDNA5 were generated as previously described [ 9 ]. 
2.5. GTP γ S binding assay 
Measurement of GTP γS binding to CHO Flp-In M1-EBI2 wt or
pcDNA5 membranes upon 7 α,25-OHC agonism or GSK682753A an-
tagonism was performed as described previously [ 9 ]. Brieﬂy, 10 μg of
membrane preparation was incubated 30 min in the presence of lig-
ands at various concentrations and [ 35 S] GTP γS at 1 nM. Wheat-germ
agglutinin-coupled SPA beads were subsequently added (2.8 mg / mL)
followed by 30 min incubation. After centrifugation (1500 rpm, 5 min)
the amount of GTP γS binding was measured using a TopCounter. Un-
speciﬁc binding was determined by adding unlabeled GTP γS at 40
μM. 
2.6. β-Arrestin recruitment 
Recruitment of β-arrestin was measured using the PathHunter β-
arrestin assay (DiscoveRx). cDNA encoding M1-EBI2 wt was fused to
the PK1-tag and the small fragment of β-galactosidase and cloned into
pcDNA3.1 + . Assays were performed in a CHO-K1 EA-arrestin cell line
stably expressing β-arrestin coupled to the β-gal large fragment. Cells
were seeded out at 20,000 / well in 96-well plates and transfected the
following day with 50 ng DNA using FuGENE6 reagent (0.15 μL / well).
48 h after transfection, cells were stimulated with varying concen-
trations of 7 α,25-OHC and / or GSK682753A for 90 min. β-Arrestin
recruitment was detected as β-gal activity 60 min after addition of
chemiluminescent substrate. 2.7. Chemotaxis 
B cells were isolated from wt and EBI2-overexpressing C57BL / 6
mice as previously described [ 16 ]. Chemotaxis was measured using
96-well ChemoTx plates with 5 μm pores. Various concentrations of
7 α,25-OHC and / or GSK682753A were applied to the lower chemo-
taxis chambers and 200,000 B cells subsequently added to the ﬁlter.
The plates were incubated for 5 h at 37 ◦C and the number of cells
migrated into the lower chambers detected using the CellTiterGlo dye
and a TopCounter. 
2.8. MAP kinase phosphorylation 
CHO cells stably expressing EBI2 or pcDNA5 were seeded out in
12-well plates. The cells were serum starved overnight and incubated
with GSK682753A and / or 7 α,25-OHC at varying concentrations (for
EBI2 and pcDNA) for 10 min. Subsequently, the cells were washed
twice, lysed in lysis buffer (100 mM Tris, 4% SDS, 20% glycerol) and
centrifuged for 5 min at 1500 rpm. 15–20 μg protein was loaded
on Bis–Tris 10% NuPAGE gels and run for 1.5 h at 140 V followed
by blotting onto PVDF membranes for 1.5 h at 30 V. The membrane
was blocked in TBST (1 × TBS with 0.1% Tween20) containing 5%
BSA followed by incubation with rabbit anti-phopho ERK or anti-
phospho p38 IgG antibody (1:1000). Following washing, the mem-
brane was incubated in blocking buffer containing goat anti-rabbit-
IgG HRP-conjugated antibody (1:10,000) and developed using Super-
Signal West Pico substrate (Pierce). The amount of phosphorylation
was measured using a FluorChem H2A camera. The membrane was
subsequently stripped using Pierce stripping buffer (Pierce) and the
procedure was then repeated with rabbit anti-ERK or anti-p38 IgG
antibody to detect total ERK or p38 levels. 
3. Results 
3.1. GSK682753A antagonizes 7 α,25-OHC-induced EBI2 activation 
GSK682753A is a piperidine-based non-peptide molecule identi-
ﬁed in a compound library screen as an EBI2 inverse agonist [ 16 ] ( Fig.
1 A). To examine the putative antagonistic properties of GSK682753A
we initially sought to determine whether GSK682753A was able to
block oxysterol-induced activation of EBI2 at the level of G pro-
tein activation. In agreement with previous studies [ 5 , 6 ], 7 α,25-
OHC, the most potent EBI2-activating oxysterol, induced GTPyS bind-
ing to membranes from CHO cells stably expressing EBI2 wt (but
not to pcDNA5 controls) when present ( Fig. 1 B; [7 α,25-OHC] = 1
nM, [GSK682753A] = 0). However, presence of GSK682753A dose-
dependently blocked EBI2 activity with an IC 50 of 0.2 μM demon-
strating that GSK682753A indeed functions as an antagonist ( Fig.
1 B). To determine whether this antagonism is competitive or non-
competitive, we investigated the effect of three different GSK682753A
concentrations on 7 α,25-OHC dose–response curves ( Fig. 2 A). As the
presence of GSK682753A resulted in a right-ward shift in 7 α,25-OHC
potency curve with only limited effect on the efﬁcacy, this suggest
that GSK682753A functions as a competitive antagonist. This is fur-
ther corroborated by Schild plot analysis showing a linear relationship
between the concentration of GSK682753A and the log (dr-1) value
( Fig. 2 B; slope: 1.4). The K d , as estimated from the x -axis interception,
is 64 nM. 
To characterize the antagonism of GSK682753A further down-
stream and in a G protein-independent pathway, we measured β-
arrestin recruitment in transiently transfected CHO cells. 7 α,25-OHC
induced β-arrestin recruitment with an EC 50 value of 0.2 μM in ac-
cordance with earlier studies [ 5 , 6 ] ( Fig. 3 A). GSK682753A also inhib-
ited β-arrestin recruitment but with a slightly higher potency than
in the GTPyS binding assay (IC 50 value of 40 nM; [7 α,25-OHC] = 1
μM) ( Fig. 3 B). We have previously shown that the Phe at position
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Fig. 1. (A) Chemical structure of GSK682753A. (B) Inhibition of [ 35 S]GTP γS binding to 
membranes from CHO cells stably expressing FLAG-tagged human EBI2 (solid squares) 
or pcDNA5 control (open circles) by GSK682753A in the presence of 1 nM 7 α,25-OHC. 
The results are mean ± SEM of raw data from three independent experiments. 
Fig. 2. (A) 7 α,25-OHC-induced [ 35 S]GTP γS binding to membranes from CHO cells sta- 
bly expressing FLAG-tagged human EBI2 or pcDNA5 (open circles) at various concentra- 
tions of GSK682753A: no antagonist ([0], solid squares), 100 nM ([ −7], solid diamonds), 
1 μM ([ −6], open squares) or 10 μM ([ −5], open triangles). The results are mean ±
SEM of raw data from three independent experiments. (B) Schild plot analysis of the 
dose–response curves presented in (A). The interception with the x -axis, which is an 
estimate of the log ( K d ) value is given. The slope of the linear regression is 1.4. 
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Fig. 3. (A) 7 α,25-OHC-induced β-arrestin2 recruitment in CHO cells transiently trans- 
fected with FLAG- and PK1-tagged human EBI2 wt (solid squares), F111Y mutant (open 
circles) or F111A mutant (open triangles). The results have been subtracted for back- 
ground (pCMV transfected cells) and are given relative to the basal level, i.e. when no 
agonist is present, in percent as mean ± SEM. The data are from at least three inde- 
pendent experiments. (B) Inhibition of β-arrestin2 recruitment in CHO cells transiently 
transfected with FLAG- and PK1-tagged human EBI2 wt (solid squares), F111Y mutant 
(open circles) or F111A mutant (open triangles) by GSK682753A in the presence of 1 
μM 7 α,25-OHC. The results have been subtracted for background (pCMV transfected 
cells) and are given relative to the basal level, i.e. when 1 μM 7 α,25-OHC but no antago- 
nist is present, in percent as mean ± SEM. The data are from at least three independent 
experiments. (C) Ex vivo chemotaxis of B cells isolated from wt (open squares) or EBI2- 
overexpressing (solid squares) mice towards a gradient of 7 α,25-OHC. The data are 
presented as chemotactic index as mean ± SEM and are from four independent exper- 
iments. (D) Inhibition of chemotaxis of EBI2-overexpressing B cells by GSK682753A in 
the presence of 0.1 nM 7 α,25-OHC. The results are given relative to the basal level, i.e. 
when 0.1 nM 7 α,25-OHC but no antagonist is present, in percent as mean ± SEM. The 
data are from three independent experiments. 
 II:08 / 3.32 in TM-III (F111) is crucial for the efﬁcacy of GSK682753A 
s an inverse agonist [ 16 ]. To determine whether this also is the case 
or GSK682753A as an antagonist we mutated F111 to Ala and Tyr. 
hereas F111 is not required for 7 α,25-OHC binding ( Fig. 3 A) it is 
ssential for the antagonism of GSK682753A as Ala but not Tyr sub- 
titution of F111 profoundly reduced the potency of GSK682753A ( Fig. 
 B). 
Finally, as 7 α,25-OHC functions as a chemoattractant [ 5 , 6 ], we ex- 
mined whether GSK682753A is able to block 7 α,25-OHC-induced 
hemotaxis of B cells in vitro . We used B cells from both wt and 
BI2-overexpressing (-OE) mice to assess the importance of EBI2 ex- 
ression level. 7 α,25-OHC induced chemotaxis that peaked at 1 nM 
n both cases ( Fig. 3 C). EBI2-OE cells tended to migrate more efﬁ- 
iently than their wt counterparts, which is in line with data from 
BI2-deﬁcient and heterozygous B cells [ 5 ]. In agreement with the re- 
ults from the GTP γS and β-arrestin recruitment assays, GSK682753A 
ose-dependently blocked the B cell migration ( Fig. 3 D; shown for 
BI2-OE cells only). Interestingly, the potency (7 pM) was much higher 
ompared to the other assays. This could however be due to a gen- 
rally higher sensitivity for ligand-modulation of EBI2 in this assay 
s also the potency of the endogenous agonist 7 α,25-OHC was in- 
reased. Thus, the EC 50 of the agonist was 0.1 nM in the chemotaxis 
ssay compared to 1 and 100 nM the GTP γS ( Fig. 2 A) and β-arrestin 
ecruitment ( Fig. 3 A) assays, respectively. 
.2. 7 α,25-OHC induces MAP kinase activation 
It has previously been shown that 7 α,25-OHC activates the G αi 
athway [ 5 , 6 ]. However, whether 7 α,25-OHC induces MAP kinase 
ctivation upon binding to EBI2 remains to be elucidated. To examine 
his, we measured ERK1 / 2 and p38 phoshorylation in CHO cells stably 
xpressing EBI2 in the presence of 7 α,25-OHC. As seen in Fig. 4 A, 
 α,25-OHC induced a dose-dependent activation of ERK1 / 2 with a 
C 50 value of 3 nM. This activation was inhibited by ptx indicating ERK1 / 2 phosphorylation to be dependent of G αi pathway activity. 
In line with this, GSK682753A also inhibited ERK1 / 2 activation with 
an IC 50 of 8 nM ( Fig. 4 B). Finally, we also examined whether EBI2 
activation results in activation of the p38 MAP kinase. As seen in 
Fig. 4 C, like ERK, p38 was dose-dependently activated by 7 α,25-OHC 
in a ptx-sensitive manner. Thus, oxysterol binding to EBI2 leads to 
activation of at least two MAP kinases. 
4. Discussion 
Much has been learned about the biology and pharmacology of 
EBI2 in the past 2 years. Thus, both the endogenous agonist [ 5 , 6 ], 
the cellular producers of this agonist [ 7 ] and the molecular pharma- 
cology of 7 α,25-OHC, the most potent agonist, [ 9 , 10 ] have all been 
characterized within this period. In addition, just prior to the deor- 
phanization, we presented a non-peptide compound, GSK682753A, 
which inhibited the apparent constitutive activity of EBI2 [ 16 ]. Here, 
we have investigated the antagonistic properties of this molecule 
showing that it blocks oxysterol-induced G protein activation ( Figs. 
1 and 2 ), β-arrestin recruitment ( Fig. 3 A and B), B cell chemotaxis 
( Fig. 3 C and D) and ERK activation ( Fig. 4 ). Compared to the in vitro
assays, the potency measured in the ex vivo chemotaxis assay was 
much higher. At present we cannot explain this difference. However, 
we have recently characterized a series of CCR8 antagonists and also 
observed higher potencies in chemotaxis assays compared to IP 3 ac- 
cumulation [ 18 ], and in line with the concomitant higher potency of 
7 α,25-OHC it is possible that an increase in assay sensitivity could be 
a contributing factor. 
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Fig. 4. (A) 7 α,25-OHC-induced ERK activation in serum-starved CHO cells stably expressing FLAG-tagged human EBI2. The data are presented as the ratio between phosphorylated 
ERK (pERK) and total ERK (tERK) as mean ± SEM from three independent experiments. Representative blots of pERK and tERK are shown below. Inset , ERK phosphorylation by 
100 nM 7 α,25-OHC in cells incubated overnight with 100 ng / mL pertussis toxin ( + ptx) or DMSO vehicle ( −ptx). (B) Inhibition of ERK activation by GSK682753A in the presence of 
1 nM 7 α,25-OHC. Presented as in (A). ( C ) 7 α,25-OHC-induced p38 activation in serum-starved CHO cells stably expressing FLAG-tagged human EBI2 in after overnight incubation 
with pertussis toxin ( + ptx, ﬁlled columns) or DMSO control ( −ptx, empty columns). The data are presented as the ratio between phosphorylated p38 (p-p38) and total p38 (t-p38) 
as mean ± SEM from three independent experiments. Representative blots of p-p38 and t-p38 are shown below. * p < 0.05 by Student’s t -test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Collectively, our results indicate that GSK682753A functions as a
competitive antagonist and binds to the receptor in the same region
as 7 α,25-OHC. First, we observe linearity in the Schild plot analy-
sis ( Fig. 2 B). Second, GSK682753A is highly dependent on F111 at
position III:08 / 3.32 in TM-III ( Fig. 3 B). Although this is not the case
for 7 α,25-OHC ( Fig. 3 A), it has recently been shown that the TM-III
residues Y112 at position III:09 / 3.33 (just next to F111) and Y116 at
III:13 / 3.37 are crucial for agonist binding [ 9 , 10 ] indicating that the
two ligands bind in the same region. Interestingly, the primary uHTS
screen at Sanford-Burnham Center for Chemical Genomics identiﬁed
2946 compounds out of 364,168 tested that were able to suppress
7 α,25-OHC-induced β-arrestin recruitment at 5 μM by more than 50%
(PubChem BioAssay ID: 651636). Of note, the most efﬁcacious of the
active compounds are very similar in structure to GSK682753A. For
instance, the best compound (CID: 5804570) also has two chlorine-
substituted benzene-rings at each extremity, an enone moiety and a
centrally-located nitrogen-containing ring (in this case a piperazine).
Thus, it seems that these structural traits are important for efﬁcacious
inhibition of EBI2 activity. It should be noted that we ﬁrst charac-
terized GSK682753A as an inverse agonist [ 16 ]. However, new data
indicate that a part of the constitutive activity of EBI2 may be a result
of oxysterol contamination in the medium [ 9 ]. Thus, the inverse ago-
nism of GSK682753A might have been antagonistic. It is possible that
EBI2 is constitutively active; however, presently we cannot assess the
magnitude of this (if any) with the tools available. 
As EBI2 is highly important for generation of an efﬁcient T cell-
dependent humoral immune response [ 5 –7 ] it may be that aber-
rant expression or other dysregulation of this receptor contributes
in B cell pathologies. In line with this, EBI2 expression is down-
regulated in diffuse large B-cell lymphomas [ 12 ] and chronic lym-
phocytic leukemia [ 13 ] but up-regulated in PTLDs [ 14 ]. Interestingly,
PTLDs are highly associated with Epstein–Barr virus (EBV) seroposi-
tivity which agrees well with the ﬁnding that EBV infection of B cells
in vitro results in transformation of these into highly proliferative
lymphoblastoids [ 19 ]. In both cases, the expression of EBI2 is highly
upregulated suggesting that this receptor could play a role in patho-
genesis [ 2 , 15 ] putatively in combination with BILF1 [ 20 ]. This is also
indicated by the observation that the proliferation of B cells over-
expressing EBI2 is higher than wt counterparts [ 16 ]. Importantly, the
proliferation could be blocked by GSK682753A suggesting that tar-
geting EBI2 could be therapeutically beneﬁcial. This may not only be
limited to malignant diseases but may also extend to EBV-associated
benign conditions such as mononucleosis for which no treatment is
currently available. 
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